ESLAW — Estrella Immunopharma, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1844417 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,292,064 | -2,292,064 | 3,657,198 | 1,927,404 | 8,927,494 |
| Dec 2025 | 0 | — | -613,199 | -613,174 | 3,176,975 | 1,384,302 | 13,543,033 |
| Sep 2025 | 0 | — | -4,801,149 | -4,801,149 | 3,523,511 | 1,626,610 | 13,359,934 |
| Jun 2025 | 0 | — | -5,544,028 | -5,544,878 | 2,980,527 | 1,316,594 | 9,075,195 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,017,708
Investing CF
$0
Financing CF
$9,523,639
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
—
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-39,282,879
Inventory
—
Receivables
$229,794
ST Investments
—
EBIT TTM
$-13,250,440
Pretax Income TTM
$-13,250,440
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -13,062,674 | -13,063,512 | 3,176,975 | 13,543,033 | — | -1,785,679 |
| Jun 2024 | 0 | -7,310,098 | -7,311,723 | 4,454,189 | 180,701 | — | -16,068,306 |
| Jun 2023 | 0 | -11,114,402 | -11,114,402 | 3,028,399 | 14,770,949 | — | -1,336,121 |
| Jun 2022 | 0 | -1,685,347 | -1,685,347 | 4,921,666 | 5,961,509 | — | -1,442,028 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AMGN | AMGEN INC | $191.70B | $355.20 | — |
| GILD | GILEAD SCIENCES, INC. | $155.93B | $125.59 | — |
| ARGX | ARGENX SE | $55.57B | $893.52 | — |
| RVMD | Revolution Medicines, Inc. | $32.71B | $153.87 | — |
| BIIB | BIOGEN INC. | $29.53B | $200.05 | — |
News headlines (Yahoo Finance, 1h cache)
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
2026-05-05 12:00 · Yahoo
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research
2026-03-23 12:00 · Yahoo
ESLA: Initiating Coverage of Estrella Immunopharma: A Potential Successor to Arcellx in Next-Generation CAR-T
2026-03-18 09:20 · Yahoo
Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either?
2025-11-04 17:13 · Yahoo
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
2025-11-03 13:00 · Yahoo
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements
2025-10-06 12:00 · Yahoo
Is Estrella Immunopharma (NASDAQ:ESLA) In A Good Position To Deliver On Growth Plans?
2025-08-14 10:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.